Behrad Derakhshan
Corporate Officer/Principal chez EDGEWISE THERAPEUTICS, INC.
Fortune : 229 919 $ au 31/05/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Kevin Koch | M | 63 | 7 ans | |
| Peter Thompson | M | 64 | 7 ans | |
| Alan Russell | M | 54 | 7 ans | |
| Badreddin Edris | M | 37 | 7 ans | |
| Jon Root | M | 64 | 5 ans | |
| Elvire Gouze | M | - |
Innoskel SASU
 Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | - |
| Laura Brege | F | 66 | 4 ans | |
| Jonathan Fox | M | 66 | 1 ans | |
| Rajul Jain | M | - |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | - |
| Rachel Maers | F | - |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | - |
| Marc Semigran | M | 67 | 2 ans | |
| Michel Detheux | M | 57 |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | 2 ans |
| John Moore | M | 59 | 4 ans | |
| Leslie Leinwand | M | - | - | |
| Joanne Donovan | M | 67 | 3 ans | |
| R. Carruthers | M | 66 | 4 ans | |
| Piyush Sharma | M | - | 7 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| David Hallal | M | 56 | 10 ans | |
| Stephen P. Squinto | M | 67 | 23 ans | |
| Felix Baker | M | 55 | 6 ans | |
| Ludwig Hantson | M | 61 | 4 ans | |
| Kenneth Harrison | M | 44 | 4 ans | |
| Tina Beamon | F | - | 3 ans | |
| Rana Strellis | F | - | 4 ans | |
| Mark Day | M | 52 | 2 ans | |
| William Keller | M | 75 | 6 ans | |
| Jens Renstrup | M | 59 | 3 ans | |
| Jeffrey Fryer | M | 55 | 9 ans | |
| Melissa Manno | F | - | 2 ans | |
| Massimiliano Colao | M | 59 | 3 ans | |
| Randy Teel | M | 45 | 2 ans | |
| Brian Krex | M | 57 | 4 ans | |
| James Loerop | M | 60 | 2 ans | |
| Richard Riese | M | 61 | 3 ans | |
| Richard Porter | M | - |
Therachon AG
| 3 ans |
| Aled Williams | M | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 1 ans |
| Martine Zimmermann | M | 55 | 7 ans | |
| Thomas-Christian Mix | M | 57 | 2 ans | |
| Lisa Trivison Beck | F | 62 | 3 ans | |
| Micah Zajic | M | 43 | 3 ans | |
| George Llado | M | 58 | - | |
| Mohammed Qatanani | M | 50 | 3 ans | |
| John Tilton | M | 56 | 10 ans | |
| Jason Meyenburg | M | 47 | 13 ans | |
| Saqib Islam | M | 54 | 3 ans | |
| Dominique Monnet | M | 65 | 1 ans | |
| Henric Bjarke | M | 57 | 5 ans | |
| Dave Anderson | M | 74 | 1 ans | |
| Stephanie Fagan | F | - | 2 ans | |
| Paresh N. Soni | M | 63 | 2 ans | |
| Bill Lundberg | M | 60 | 4 ans | |
| Jeremy Springhorn | M | 61 | 9 ans | |
| Jeroen van Beek | M | - | 10 ans | |
| Vikas Sinha | M | 60 | 11 ans | |
| Jing Marantz | M | 58 | 2 ans | |
| Julie O'Neill | F | 58 | 3 ans | |
| Mittie Doyle | M | 59 | 3 ans | |
| Radhika Tripuraneni | M | 44 | - | |
| Al Boyle | M | - | 6 ans | |
| Derek Adams | M | 50 | 11 ans | |
| Joseph Newell | M | 54 | 2 ans | |
| James Engelhart | M | 60 | 2 ans | |
| Julie VanOrsdel Daves | F | - | 3 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 57 | 90,48% |
| France | 4 | 6,35% |
| Suisse | 2 | 3,17% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Behrad Derakhshan
- Réseau Personnel
